US2018305667A1PendingUtilityA1
Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
Est. expirySep 22, 2028(~2.2 yrs left)· nominal 20-yr term from priority
A61P 31/04C07K 14/4705C12Y 502/01008C12N 9/90C07K 14/70578C07K 2319/033C12N 2501/52C12N 15/86C12N 2501/998A61P 31/00C07K 14/4702C12N 7/00C12N 2510/00A61P 43/00A61P 37/04C12N 2710/10343A61P 35/00C12N 2501/70A61K 2039/5156C12N 5/0639A61K 40/42A61K 40/30A61K 40/24A61K 40/19A61K 40/11A61K 40/10A61K 40/00A61K 2239/38A61K 2239/31
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.
Claims
exact text as granted — not AI-modified1 - 16 . (canceled)
17 . A nucleic acid comprising a promoter operatively linked to a polynucleotide encoding a chimeric protein, wherein the chimeric protein comprises
(a) a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain, (b) a truncated MyD88 polypeptide lacking the TIR domain, wherein the truncated MyD88 polypeptide comprises amino acid residues 1-172 and does not include contiguous amino acid residues 173-296 of a full length native human MyD88 polypeptide; and (c) an FKBP12 multimeric ligand-binding region.
18 . The nucleic acid of claim 17 , wherein FKBP12 multimeric ligand-binding region binds to AP1903 or AP20187.
19 . The nucleic acid of claim 17 , wherein the multimeric ligand-binding region comprises an FKBP12 polypeptide.
20 . The nucleic acid of claim 17 , wherein the multimeric ligand-binding region comprises a FKBP12 ligand-binding region comprising an amino acid substitution at position 36.
21 . The nucleic acid of claim 17 , wherein the FKBP12 multimeric ligand-binding region comprises a FKBP12(V36) polypeptide.
22 . The nucleic acid of claim 17 , wherein the FKBP12 multimeric ligand-binding region comprises two FKBP12(V36) polypeptides.
23 . The nucleic acid of claim 17 , wherein the nucleic acid is isolated.
24 . The nucleic acid of claim 17 , wherein the ligand binding region is amino terminal to the CD40 cytoplasmic polypeptide region of the chimeric protein.
25 . The nucleic acid of claim 17 , wherein the nucleic acid is contained within a vector.
26 . The nucleic acid of claim 25 , wherein the nucleic acid is contained within a viral vector.
27 . The nucleic acid of claim 25 , wherein the nucleic acid is contained within a plasmid vector.
28 . A cell transduced or transfected with a vector of claim 25 .
29 . A method for activating a cell, comprising transfecting or transducing the cell with a vector of claim 25 , and contacting the transfected or transduced cell with a ligand that binds to the ligand binding region, whereby the cell is activated.
30 . The method of claim 29 , wherein the ligand is AP1903 or AP20187.Join the waitlist — get patent alerts
Track US2018305667A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.